REFERENCE FILE
Cagrilintide
Read the record, then work through the questions.
Reference details
Status as of
- Regulatory category
- Investigational
- Evidence category
- Randomized evidence
- Mechanism
- A long-acting amylin analogue.
- Evidence
- A randomized weight-management trial was funded by Novo Nordisk.
- Limitations
- Combination results cannot be assigned to a single ingredient.
- Safety
- The trial reported gastrointestinal and injection-site reactions.
- Formulation and route
- Studied as a subcutaneous injection.
- Approval scope
- Investigational; no FDA-approved product.
A SECOND LOOK
A question to carry into the reading
For a comparison involving cagrilintide, first write down the difference that would matter for your question. Then locate the estimate of that comparison and any uncertainty interval attached to it. Copy them onto one line with the measure and unit. If you find only separate group estimates, do not invent an interval for their difference. Mark the comparison's precision as a question to resolve. Examine whether the reported interval distinguishes the difference you specified, rather than ranking central values alone. End with two separate notes: the size suggested by the estimate and the range of possibilities left open by its reported uncertainty.
Questions to keep beside the page
- Where does the report provide uncertainty around the estimate I am comparing?
- What difference would matter for the question behind my comparison?
- Does the available uncertainty support that distinction, or leave it unresolved?
Sources for this file
FROM THE REFERENCE DESK